"Over the past 2 decades, male pattern baldness has repeatedly and consistently been found to be associated with an increased risk for prostate cancer in observational studies.
The tie makes theoretical sense in terms of physiology bec"...
The maximum amount of Indium In 111 ProstaScint® (capromab pendetide) that can be safely administered has not been determined. In clinical studies, single doses of 10 mg of Indium In 111 ProstaScint® were administered to 20 patients with prostate cancer; the type and frequency of adverse reactions at this dose were similar to those observed with lower doses. The maximum Indium In 111 dose administered with ProstaScint® in a clinical study was 6.5 mCi.
Indium In 111 ProstaScint® (capromab pendetide) should not be used in patients who are hypersensitive to this or any other product of murine origin or to Indium In 111 chloride.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 5/13/2016
Additional ProstaScint Kit Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.